Methyl palmitate

Methyl palmitate is a naturally occurring fatty acid ester. Methyl palmitate is a potent inhibitor of ΙκB phosphorylation. Methyl palmitate modulates macrophage activity and down-regulates pro-inflammatory mediators such as TNF-α and nitric oxide (NO). Methyl palmitate possesses anti-inflammatory and antifibrotic effects. Methyl palmitate can inhibit LPS (HY-D1056)-induced Kupffer cells and rat peritoneal macrophages. Methyl palmitate is able to inhibit the phagocytic function of RAW cells. Methyl palmitate is antagonistic to muscarinic receptors. Methyl palmitate exerts cardioprotective effects against ischemia/reperfusion injury in vivo. Methyl palmitate is highly toxic against adult T. cinnabarinus^{[1][2][3][4][5]}. In Vitro: Methyl palmitate (Compound MP) (0.25-1 mM, 24 h) reduces the phagocytic activity and nitrite production dose-dependently in RAW cells^[1].
Methyl palmitate (75 μM) significantly reduces the I/R-decreased cell viability in cardiomyocytes and increases the level of p-AKT^[5]. In Vivo: Methyl palmitate (Compound MP) (75-150 mg/kg, i.p., single dose) significantly reduces Carrageenan (HY-125474)-induced paw edema in Wistar rats^[4].
Methyl palmitate (150 mg/kg, i.p., single dose) significantly inhibits IL-6 and TNF-α in Wistar rats^[4].
Methyl palmitate (300 mg/kg, i.v., 5 min before reperfusion) attenuates the I/R-induced myocardium infarct size and significantly reduces the level of CK-MB in I/R-injured heart cardiomyocytes of rat model^[5].